Forum for Science, Industry and Business

More than half of depression patients give up their treatment

23.11.2010

Most patients who take anti-depressants give up their treatment in less than six months, the minimum period recommended for treating severe depression and other derived pathologies. This is the conclusion of a new study carried out by Catalan researchers, which reveals that only 25% continue their treatment for more than 11 months.

"Only one in every five patients properly completes their treatment", Catalina Serna, co-author of the study, and an expert at the Jordi Gol Primary Care Research Institute (IDIAP) in Lleida, tells SINC.

From 2003 to 2007, researchers from the Catalan Institute of Health (ICS) and the IDIAP Jordi Gol analysed 7,525 patients who were starting anti-depression treatment, looking at how long they continued with this treatment and the reasons why they gave it up.

The results, published this year in the journal European Psychiatry, pointed out that, of the 3.2% of the population who started treatment for depression, 56% stopped taking their medication during the first four months, and less than 25% of the cohort continued their treatment for more than 11 months.

The researchers say patients are most likely to give up their medication during the acute stage of depression (the first months). "The levels to which they stick to their treatment also declines steeply between the first four and 12 months of the monitoring period", Serna points out.

"In our study, only 22% of patients completed their treatment", the expert explains. "The higher completion rates seen in chronic cases are in multiply-medicated patients, who are twice as likely as other patients to continue with their treatment for depression (31% vs. 15.3%).

Men are more likely to give up treatment

Meanwhile, men are more at risk of giving up their treatment earlier than women (50% of men gave up their medication after two months, while 50% of women gave it up after three months).

Depression is one of the commonest psychiatric diseases among adults, above all in industrialised countries. A European study carried out in 2004 found that almost 13% of individuals surveyed reported having a serious depressive illness at some point in their lives. This study revealed that in Spain, where anti-depressant use has risen in line with the availability of new drugs, 10.5% of the population suffers from depression.

Die letzten 5 Focus-News des innovations-reports im Überblick:

Controlling electronic current is essential to modern electronics, as data and signals are transferred by streams of electrons which are controlled at high speed. Demands on transmission speeds are also increasing as technology develops. Scientists from the Chair of Laser Physics and the Chair of Applied Physics at Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU) have succeeded in switching on a current with a desired direction in graphene using a single laser pulse within a femtosecond ¬¬ – a femtosecond corresponds to the millionth part of a billionth of a second. This is more than a thousand times faster compared to the most efficient transistors today.

At the productronica trade fair in Munich this November, the Fraunhofer Institute for Laser Technology ILT will be presenting Laser-Based Tape-Automated Bonding, LaserTAB for short. The experts from Aachen will be demonstrating how new battery cells and power electronics can be micro-welded more efficiently and precisely than ever before thanks to new optics and robot support.

Fraunhofer ILT from Aachen relies on a clever combination of robotics and a laser scanner with new optics as well as process monitoring, which it has developed...

Plants and algae use the enzyme Rubisco to fix carbon dioxide, removing it from the atmosphere and converting it into biomass. Algae have figured out a way to increase the efficiency of carbon fixation. They gather most of their Rubisco into a ball-shaped microcompartment called the pyrenoid, which they flood with a high local concentration of carbon dioxide. A team of scientists at Princeton University, the Carnegie Institution for Science, Stanford University and the Max Plank Institute of Biochemistry have unravelled the mysteries of how the pyrenoid is assembled. These insights can help to engineer crops that remove more carbon dioxide from the atmosphere while producing more food.

Our brains house extremely complex neuronal circuits, whose detailed structures are still largely unknown. This is especially true for the so-called cerebral cortex of mammals, where among other things vision, thoughts or spatial orientation are being computed. Here the rules by which nerve cells are connected to each other are only partly understood. A team of scientists around Moritz Helmstaedter at the Frankfiurt Max Planck Institute for Brain Research and Helene Schmidt (Humboldt University in Berlin) have now discovered a surprisingly precise nerve cell connectivity pattern in the part of the cerebral cortex that is responsible for orienting the individual animal or human in space.